Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masazumi Fujii has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cerebrospinal fluid soluble protein tyrosine phosphatase receptor type Z detected with human natural killer-1 antibody as a practical biomarker for glioma diagnosis

    by Yu Naruse, Masazumi Fujii, Kenichiro Nagai, Ryo Hiruta, Toshie Sakagami, Takuru Kobayashi, Kazuto Takahashi, Junko Iijima, Hideaki Suzuki, Kasumi Hattori, et al.

    Background: A major challenge in managing gliomas is the lack of reliable and clinically applicable biomarkers. Imaging alone is often insufficient to distinguish gliomas from primary central nervous system lymphoma (PCNSL), necessitating invasive biopsy. Soluble protein tyrosine phosphatase receptor type Z (sPTPRZ) in cerebrospinal fluid (CSF) has recently emerged as a promising candidate. We evaluated the diagnostic utility of CSF sPTPRZ in differentiating gliomas from PCNSL. Methods: We developed an anti-HNK-1 antibody-based ELISA for CSF sPTPRZ and analyzed 51 glioma, 15 PCNSL, and 20 control patients. Complementary assays included western blotting, immunohistochemistry, qPCR. sPTPRZ immunopurified from glioma CSF was used to determine HNK-1 epitope sites. RNA-seq data from the C-CAT database were used to identify PTPRZ gene fusions. Results: CSF sPTPRZ levels were significantly elevated in glioma patients compared with both controls and PCNSL, demonstrating robust discrimination between these entities (AUC = 0.910 vs controls; AUC = 0.805 vs PCNSL; P = .0010). PTPRZ expression was absent in PCNSL, consistent with low CSF sPTPRZ. Mass spectrometry localized the HNK-1 epitope to exon 12 of PTPRZ-long, absent in PTPRZ-MET fusion variants (2% of gliomas). These insights may explain low sPTPRZ levels in a subset of gliomas. Conclusion: CSF sPTPRZ detection with anti-HNK-1 antibody is a minimally invasive biomarker for glioma. It significantly improves diagnostic discrimination from PCNSL, and provides a molecular rationale for biomarker-negative glioma subsets with PTPRZ-MET fusions.

  • Open Access

    Analysis of PTPRZ expression in glioma and schwannoma — PTPRZ-long is highly expressed and shed in glioma —

    by Haruhiko Kikuta, Masazumi Fujii, Yu Naruse, Kenichiro Nagai, Ryo Hiruta, Toshie Sakagami, Takuru Kobayashi, Kazuto Takahashi, Shunichi Koriyama, Taiichi Saito, et al.

  • Open Access

    Development and Validation of a Multimodal Optico-Radiological Image System for Neurosurgical Guidance: A Proof of Concept

    by Dilip Bhandari, Mudathir Bakhit, Yuichiro Hayashi, Ryo Hiruta, Kiyoshi Saito, Kensaku Mori, Masazumi Fujii

    Introduction Advancements in neurosurgery have integrated imaging modalities like fluorescence imaging and neuronavigation to enhance tumor resection and functional preservation. However, aligning intra-operative optical data, such as 5-aminolaevulinic acid (5-ALA) fluorescence and direct cortical stimulation (DCS) tags, with radiological images remains challenging due to brain shift. To address this, we developed the Multimodal Optico-Radiological Image (MORI) platform, a proof-of-concept system integrating intra-operative optical imaging with MRI/CT for improved surgical visualization. Methods We evaluated MORI in 19 brain tumor surgeries near eloquent or deep-seated areas. The system comprised (1) optical image capture, (2) 3D surface reconstruction from stereo optical images, (3) registration of optical and radiological images using the iterative closest point (ICP) algorithm, and (4) visualization. Accuracy was validated by measuring registration errors between anatomical landmarks. Results MORI reconstructed 3D brain surfaces, integrating fluorescence and functional mapping with MRI. The system achieved an average registration error of 2.2 mm across 10 cases. Case studies demonstrated precise overlay of DCS tags onto MRI for eloquent area localization and 5-ALA fluorescence for tumor margin delineation. Additionally, MORI converted conventional 2D surgical videos into a 4D surgical record for timeline-based integration. Conclusion MORI enhances neurosurgical precision by dynamically integrating optical and radiological imaging. Future advancements, such as automation and surgical microscope integration, could refine it into a robust navigation tool, improving intra-operative decision-making, surgical education, and patient outcomes while advancing neurosurgical research.

  • Open Access

    Effectiveness of CI as an alternative to ABI for hearing loss in patients with vestibular schwannomas: A multicenter study in Japan

    by Mitsuyoshi Imaizumi, Hidehiko Takeda, Shujiro Minami, Naoki Oishi, Daisuke Yamauchi, Shigeyuki Murono, Hirofumi Nakatomi, Kiyoshi Saito, Akio Morita, Masazumi Fujii


  • Exo- and endoscopic lateral orbital wall approach for the medial temporal lobe glioma: how I do it

    by Kenichiro Iwami, Masazumi Fujii, Tadashi Watanabe, Koji Osuka

    Background The endoscopic transorbital approach provides a direct access to the medial temporal lobe (MTL). However, when excising a highly vascular tumour, a wider access route that enables the concurrent use of standard neurosurgical instruments with both hands is preferable. Method We described the concept and technique of the lateral orbital wall approach (LOWA), which comprises orbitotomy and mini-craniotomy to treat MTL lesions using an exoscope and endoscope. Conclusion The LOWA provides a safe and natural surgical corridor to the MTL and enables 2- or 3-hand surgery. Hence, LOWA can potentially improve safety and efficiency to treat MTL lesions.


  • Open Access

    Protein Tyrosine Phosphatase Receptor Type Z in Central Nervous System Disease

    by Kenichiro Nagai, Masazumi Fujii, Shinobu Kitazume

    Gliomas are among the most common tumors of the central nervous system and include highly malignant subtypes, such as glioblastoma, which are associated with poor prognosis. Effective treatments are therefore urgently needed. Despite the recent advances in neuroimaging technologies, differentiating gliomas from other brain diseases such as multiple sclerosis remains challenging in some patients, and often requires invasive brain biopsy. Protein tyrosine phosphatase receptor type Z (PTPRZ) is a heavily glycosylated membrane protein that is highly expressed in the central nervous system. Several reports analyzing mouse tumor models suggest that PTPRZ may have potential as a therapeutic target for gliomas. A soluble cleaved form of PTPRZ (sPTPRZ) in the cerebrospinal fluid is markedly upregulated in glioma patients, making it another promising diagnostic biomarker. Intriguingly, PTPRZ is also involved in the process of remyelination in multiple sclerosis. Indeed, lowered PTPRZ glycosylation by deletion of the glycosyltransferase gene leads to reduced astrogliosis and enhanced remyelination in mouse models of demyelination. Here, we review the expression, molecular structure, and biological roles of PTPRZ. We also discuss glioma and demyelinating diseases, as well as the pathological role of PTPRZ and its application as a diagnostic marker and therapeutic target.


  • Open Access

    覚醒下手術症例を対象とした, 頭頂葉性の高次運動機能を評価する課題の開発

    by Kazuaki Shigihara, Masazumi Fujii, Nao Akutagawa, Miyako Futamura, Naoyuki Oi

    脳腫瘍術後, 職場復帰を含めた真の意味の QOL 維持には, 単純な運動だけでなく, より高次の運動機能の温存が求められる。覚醒下手術は, 言語・単純な運動機能評価を中心に普及が進んでいるが, より高次の運動機能を評価する手法は確立されていない。我々は, 覚醒下手術の, 主に頭頂葉の術中高次運動機能評価として, PEG&COIN 課題とスポンジコントロール課題の 2 つを開発し, 連続 4 例で検討した。 前者は把握と注視下到達動作の, 後者は体性感覚に依存した動作の評価法として, 電気刺激によるマッピング (機能の有無を調べること) と術中の運動機能のモニタリング (機能状態を評価すること) 両者の目的で用いた。前半の 2 例では, PEG&COIN 課題のみを実施したが, 術後体性感覚依存動作の障害を認めた。 両者を併用した後半 2 例では術後の巧緻運動温存が可能であった。頭頂葉性の高次運動機能評価として両者の併用が有用であると期待される。

  • [Current Topics on Precision Medicine for Neurofibromatosis Type 2].

    by Ryo Hiruta, Masazumi Fujii

    Neurofibromatosis type 2(NF2)is a hereditary condition that causes bilateral vestibular schwannomas(VS), multiple schwannomas, and meningiomas. The prognosis is poor because the multiplicity of the tumors leads to a progressive decline in the quality of life, deafness, and death in an early age. NF2 is caused by a disorder in the tumor suppressor gene NF2, which encodes the merlin protein. Although it is an autosomal dominant disease, more than half of cases are presumed to be de novo caused by somatic mosaicism, the diagnosis rate of which has been improved by the recently introduced technology of targeted deep sequencing of DNA from multiple tissues. No chemotherapeutic drugs for treating NF2-related VS are available at present, and surgery and radiotherapy remain the only therapeutic options. Recently, a randomized, double-blind, multicenter clinical trial has started in Japan to verify the efficacy and safety of bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor, in treating NF2-related VS.

  • Surgical Classification of Radical Temporal Bone Resection and Transcranial Tympanotomy: A Retrospective Study from the Neurosurgical Perspective

    by Kenichiro Iwami, Masazumi Fujii, Naoki Nishio, Takashi Maruo, Tadao Yoshida, Nobuaki Mukoyama, Koji Osuka, Keisuke Takanari, Kenta Murotani, Yuzuru Kamei, et al.